{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Distress+Syndrome&page=2",
    "query": {
      "condition": "Severe Acute Respiratory Distress Syndrome",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Distress+Syndrome&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:53:35.575Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04511650",
      "title": "Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Acute Respiratory Distress Syndrome (ARDS)"
      ],
      "interventions": [
        {
          "name": "Razuprotafib Subcutaneous Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Subcutaneous Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2020-10-21",
      "completion_date": "2021-02-26",
      "has_results": true,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04511650"
    },
    {
      "nct_id": "NCT01314066",
      "title": "Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Sepsis",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-07",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-05-03",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01314066"
    },
    {
      "nct_id": "NCT04402060",
      "title": "A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID",
        "Covid-19",
        "Coronavirus",
        "Coronavirus Infection",
        "Severe Acute Respiratory Syndrome",
        "Severe Acute Respiratory Syndrome Coronavirus 2",
        "Sars-CoV2",
        "Ards",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "APL-9",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2020-05-28",
      "completion_date": "2021-02-13",
      "has_results": true,
      "last_update_posted_date": "2022-03-23",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 16,
      "location_summary": "Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402060"
    },
    {
      "nct_id": "NCT00431158",
      "title": "ARDSnet Protocol vs. Open Lung Approach in ARDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Respiratory Distress Syndrome, Adult"
      ],
      "interventions": [
        {
          "name": "Different Mechanical Ventilation Protocols",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 224,
      "start_date": "2007-01",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-09-18",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00431158"
    },
    {
      "nct_id": "NCT04334148",
      "title": "Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adrian Hernandez",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1360,
      "start_date": "2020-04-22",
      "completion_date": "2021-01-09",
      "has_results": true,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 34,
      "location_summary": "Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Leesburg",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04334148"
    },
    {
      "nct_id": "NCT04750278",
      "title": "A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Severe to Critical COVID 19 With Associated ARDS"
      ],
      "interventions": [
        {
          "name": "FP-025 100 mg",
          "type": "DRUG"
        },
        {
          "name": "FP-025 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foresee Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2021-04-06",
      "completion_date": "2022-04-18",
      "has_results": true,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 8,
      "location_summary": "Chula Vista, California • La Mesa, California • Rockville, Maryland + 4 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Minto",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04750278"
    },
    {
      "nct_id": "NCT04357730",
      "title": "Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Acute Respiratory Syndrome",
        "Respiratory Failure",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Alteplase 50 MG [Activase]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denver Health and Hospital Authority",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-05-14",
      "completion_date": "2021-09-30",
      "has_results": true,
      "last_update_posted_date": "2022-01-20",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 9,
      "location_summary": "La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04357730"
    },
    {
      "nct_id": "NCT00113685",
      "title": "Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Respiratory Distress Syndrome, Adult",
        "Head Injuries, Closed",
        "Shock",
        "Shock, Traumatic"
      ],
      "interventions": [
        {
          "name": "Hypertonic Saline-Dextran Solution",
          "type": "DRUG"
        },
        {
          "name": "Lactated Ringer's Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 209,
      "start_date": "2003-04",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2021-05-03",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113685"
    },
    {
      "nct_id": "NCT04388826",
      "title": "COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Distress Syndrome, Adult"
      ],
      "interventions": [
        {
          "name": "Veru-111",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veru Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2020-06-18",
      "completion_date": "2021-08-13",
      "has_results": true,
      "last_update_posted_date": "2022-10-27",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Saint Louis Park, Minnesota • Saint Paul, Minnesota + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Vineland",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04388826"
    },
    {
      "nct_id": "NCT04365985",
      "title": "Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Acute Respiratory Distress Syndrome",
        "Severe Acute Respiratory Syndrome (SARS)",
        "Coronavirus Infections"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Corewell Health East",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-04-29",
      "completion_date": "2021-04-01",
      "has_results": true,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-05-22T07:53:35.575Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04365985"
    }
  ]
}